Which meeting are you claiming credit for?
*
Monday, September 30th - Tulane University
Friday, September 27th - University of Louisville
Tuesday, September 17th - University of Kentucky
Thursday, August 22nd - UW Medicine
Friday, July 5th - NYU Langone Health
Wednesday, May 29th - AdventHealth Orlando
Full Name
*
Email
*
example@example.com
Institution
Degrees
1. The most commonly found antibody in myasthenia gravis is:
a. Antibody to muscle specific kinase protein
b. Antibody to lipoprotein receptor-related protein 4
c. Antibody to acetylcholine receptor protein
d. Antibody to titin protein
2. Pathogenic mechanisms of myasthenia gravis include all but:
a. Antibody blocking of acetylcholine binding to the receptor
b. Enhance internalization and degradation of the acetylcholine receptor
c. Antibody activation of the terminal complement cascade
d. Antibody blockade of the sodium channel
3. The neonatal Fc receptor is:
a. A salvage pathway for immunoglobulin G
b. A salvage pathway for immunoglobulin G and M
c. A receptor protein that inhibits antibody formation
d. A receptor protein that promotes complement activation
4. Efgartigimod is:
a. A monoclonal antibody targeting the neonatal Fc receptor
b. A monoclonal antibody that promotes degradation of albumin and IgG
c. A small IgG1 Fc fragment that binds to the neonatal Fc receptor
d. A small IgG1 Fc fragment that blocks the cytoplasmic lysosomes
5. The ADAPT phase 3 Trial for myasthenia gravis demonstrated efficacy in response compare to placebo in:
a. MG-ADL score but not QMG score
b. Minimal Symptom Expression score only
c. QMG score but not MG-ADL score
d. MG-ADL and QMG scores
Submit
Should be Empty: